NCT03454854 (APP) is a NA clinical trial of intelligent terminal APP in Antithrombotic, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT03454854?

NCT03454854 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT03454854?

Interventions in NCT03454854: intelligent terminal APP.

What condition does NCT03454854 study?

NCT03454854 studies Antithrombotic.

Is NCT03454854 still recruiting?

NCT03454854 is currently status unknown. Last updated 24 May 2018.

Last reviewed 2018-05-24 · How we verify

NCT03454854: APP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of the Application(APP) on Individualized Antithrombotic Therapy

Status unknown NA Last updated 24 May 2018

What this trial tests

NA trial testing intelligent terminal APP in Antithrombotic in 10,000 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
30 December 2019

20 December 2020

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10,000
Start date	1 November 2017
Primary completion	30 December 2019
Estimated completion	20 December 2020
Sites	1 location across China

Drugs / interventions tested

intelligent terminal APP

Conditions studied

Antithrombotic — all drugs for Antithrombotic →

Sponsor

Guangdong Provincial People's Hospital

Who can join

18 and older, any sex, with Antithrombotic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal application(APP), establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03454854 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 24 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03454854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing